Sunday, October 4, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 26, 2026

Merrill and Bank of America Private Bank Launch AI-Powered Meeting Journey

View original at finance.yahoo.com
Merrill and Bank of America Private Bank Launch AI-Powered Meeting Journey AI solution modernizes the full lifecycle of client engagement New capability can save financial advisors up to four hours per meeting across millions of meetings annually Key Points Merrill and Bank of America Private Bank introduce an AI-power…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • By leveraging AI at scale across our global operations, we are expanding capabilities, optimizing process efficiency, and driving exceptional client service

    60% confidence

  • AI-Powered Meeting Journey represents a meaningful advancement in how the wealth management industry uses AI

    60% confidence

  • Early users of the Meeting Prep and Meeting Summarization capabilities are already seeing significant improvements in their workflows

    60% confidence

  • The AI solution can save financial advisors up to four hours per meeting across millions of meetings annually

    60% confidence

  • AI is helping transform employee productivity and strengthen operational excellence

    60% confidence

  • This is time our teams are reinvesting into client engagement, with even more proactive guidance and meaningful support

    60% confidence

  • This solution empowers advisors to shift capacity toward activities that drive business growth and strengthen how we serve clients

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com